腹腔镜磁力括约肌增强术与双倍剂量质子泵抑制剂治疗胃食管反流病中重度反流的随机对照试验
该随机对照试验纳入152例每日一次质子泵抑制剂治疗8周后仍有中重度反流的胃食管反流病患者,按2:1随机分为双倍剂量质子泵抑制剂组(N=102)与腹腔镜磁力括约肌增强术组(N=50)。6个月时,磁力括约肌增强术组反流缓解率按符合方案集分析为89%(42/47) vs 双倍剂量质子泵抑制剂组10%(10/101),按意向性分析为84%(42/50) vs 10%(10/102),差异均有统计学意义(P < .001)。
要点
- 每日一次质子泵抑制剂治疗8周后仍有中重度反流者,磁力括约肌增强术6个月反流缓解率高于双倍剂量质子泵抑制剂。
- 磁力括约肌增强术组81%(38/47)患者胃食管反流病健康相关生活质量评分改善≥50%,双倍剂量质子泵抑制剂组为8%(7/87)(P < .001)。
- 磁力括约肌增强术组28%报告一过性吞咽困难,4%报告持续性吞咽困难,未观察到显著安全问题。
核心结论
- 对于每日一次质子泵抑制剂治疗后仍有中重度反流的胃食管反流病患者,应考虑微创磁力括约肌增强术治疗而非增加质子泵抑制剂剂量。
研究设计与样本
- 前瞻性随机对照试验,在美国21个中心纳入152例年龄≥21岁、每日一次质子泵抑制剂治疗8周后仍有中重度反流的胃食管反流病患者,按2:1随机分为双倍剂量质子泵抑制剂组(N=102)与腹腔镜磁力括约肌增强术组(N=50)。
- 基线及6个月时进行标准化前肠症状问卷和动态食管反流监测。
主要发现
- 6个月主要终点时,符合方案集分析中磁力括约肌增强术组89%(42/47)报告反流缓解,双倍剂量质子泵抑制剂组为10%(10/101)(P < .001)。
- 意向性分析中,磁力括约肌增强术组84%(42/50)达到主要终点,双倍剂量质子泵抑制剂组为10%(10/102)(P < .001)。
- 磁力括约肌增强术组81%(38/47)患者胃食管反流病健康相关生活质量评分改善≥50%,双倍剂量质子泵抑制剂组为8%(7/87)(P < .001);磁力括约肌增强术组91%(43/47)患者停用质子泵抑制剂。
- 6个月时,磁力括约肌增强术组反流事件次数正常者占91%(40/44),双倍剂量质子泵抑制剂组为58%(46/79)(P < .001);酸暴露正常者分别占89%(39/44)与75%(59/79)(P = .065)。
- 未观察到显著安全问题;磁力括约肌增强术组28%报告一过性吞咽困难,4%报告持续性吞咽困难。
关键数值与推荐
- 反流缓解主要终点:磁力括约肌增强术组符合方案集89%(42/47) vs 双倍剂量质子泵抑制剂组10%(10/101),P < .001;意向性分析84%(42/50) vs 10%(10/102),P < .001。
- 胃食管反流病健康相关生活质量评分改善≥50%:磁力括约肌增强术组81%(38/47) vs 双倍剂量质子泵抑制剂组8%(7/87),P < .001。
- 停用质子泵抑制剂:磁力括约肌增强术组91%(43/47)。
- 反流事件次数正常:磁力括约肌增强术组91%(40/44) vs 双倍剂量质子泵抑制剂组58%(46/79),P < .001;酸暴露正常:89%(39/44) vs 75%(59/79),P = .065。
临床怎么用
- 对于每日一次质子泵抑制剂治疗后仍有中重度反流的胃食管反流病患者,作者认为应考虑微创磁力括约肌增强术治疗而非增加质子泵抑制剂剂量。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: GERD patients frequently complain of regurgitation of gastric contents. Medical therapy with proton-pump inhibitors (PPIs) is frequently ineffective in alleviating regurgitation symptoms, because PPIs do nothing to restore a weak lower esophageal sphincter. Our aim was to compare effectiveness of increased PPI dosing with laparoscopic magnetic sphincter augmentation (MSA) in patients with moderate-to-severe regurgitation despite once-daily PPI therapy. METHODS: One hundred fifty-two patients with GERD, aged ≥21 years with moderate-to-severe regurgitation despite 8 weeks of once-daily PPI therapy, were prospectively enrolled at 21 U.S. sites. Participants were randomized 2:1 to treatment with twice-daily (BID) PPIs (N = 102) or to laparoscopic MSA (N = 50). Standardized foregut symptom questionnaires and ambulatory esophageal reflux monitoring were performed at baseline and at 6 months. Relief of regurgitation, improvement in foregut questionnaire scores, decrease in esophageal acid exposure and reflux events, discontinuation of PPIs, and adverse events were the measures of efficacy. RESULTS: Per protocol, 89% (42/47) of treated patients with MSA reported relief of regurgitation compared with 10% (10/101) of the BID PPI group (P < .001) at the 6-month primary endpoint. By intention-to-treat analysis, 84% (42/50) of patients in the MSA group and 10% (10/102) in the BID PPI group met this primary endpoint (P < .001). Eighty-one percent (38/47) of patients with MSA versus 8% (7/87) of patients with BID PPI had ≥50% improvement in GERD-health-related quality of life scores (P < .001), and 91% (43/47) remained off of PPI therapy. A normal number of reflux episodes and acid exposures was observed in 91% (40/44) and 89% (39/44) of MSA patients, respectively, compared with 58% (46/79) (P < .001) and 75% (59/79) (P = .065) of BID PPI patients at 6 months. No significant safety issues were observed. In MSA patients, 28% reported transient dysphagia; 4% reported ongoing dysphagia. CONCLUSION: Patients with GERD with moderate-to-severe regurgitation, especially despite once-daily PPI treatment, should be considered for minimally invasive treatment with MSA rather than increased PPI therapy. (Clinical trial registration number: NCT02505945.).
引用
- Bell R, Lipham J, Louie B, et al. Laparoscopic magnetic sphincter augmentation versus double-dose proton pump inhibitors for management of moderate-to-severe regurgitation in GERD: a randomized controlled trial. Gastrointest Endosc. 2018. PMID: 30031018. doi:10.1016/j.gie.2018.07.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。